Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
We report two patients with Ph-positive ALL who remained bcr-abl positive after stem cell transplantation; bcr-abl negativity was successfully achieved by inducing acute GVHD either by DLI or rapid ...
Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results